ArticleIntensive care medicine2016
Personalized medicine for ARDS: the 2035 research agenda.
Article in Intensive care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Post-hoc mediation analysis of two biomarkers, and survival in acute respiratory distress syndrome.Scientific reports · 2025Trial
- Trial
- Effect of driving pressure on mortality in ARDS patients during lung protective mechanical ventilation in two randomized controlled trials.Critical care (London, England) · 2016Trial
- Bedside assessment of the effects of positive end-expiratory pressure on lung inflation and recruitment by the helium dilution technique and electrical impedance tomography.Intensive care medicine · 2016Trial
- Morphological subphenotypes of acute pancreatitis-related acute respiratory distress syndrome.Critical care (London, England) · 2026Article
- Circulating and Respiratory Biomarkers in Sepsis-Induced ARDS: Diagnostic and Prognostic Insights - A Narrative Review.Journal of inflammation research · 2026Review
- Study on subtyping and Traditional Chinese Medicine treatment of depression based on machine learning and text mining.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Soluble Fms-Like Tyrosine Kinase-1 Associates With Risk of Acute Respiratory Distress Syndrome and Mortality in Sepsis.Critical care explorations · 2025Article
- Old and New Definitions of Acute Respiratory Distress Syndrome (ARDS): An Overview of Practical Considerations and Clinical Implications.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- An animal model of severe acute respiratory distress syndrome for translational research.Laboratory animal research · 2025Article
- The protagonist of contemporary and emerging nanotechnology-based theranostics and therapeutic approaches in reshaping intensive care unit.Saudi medical journal · 2024Review
- ARDSFlag: an NLP/machine learning algorithm to visualize and detect high-probability ARDS admissions independent of provider recognition and billing codes.BMC medical informatics and decision making · 2024Article
- PNSC928, a plant-derived compound, specifically disrupts CtBP2-p300 interaction and reduces inflammation in mice with acute respiratory distress syndrome.Biology direct · 2024Article
- Endotyping in ARDS: one step forward in precision medicine.European journal of medical research · 2024Article
- Establishment of a Predictive Model for Acute Respiratory Distress Syndrome in Patients with Bacterial Pneumonia.Journal of inflammation research · 2024Article
- Identification of potential biomarkers and therapeutic targets for posttraumatic acute respiratory distress syndrome.BMC medical genomics · 2023Article
- Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome.The Lancet. Respiratory medicine · 2023Review
- The role of nanotechnology-based approaches for clinical infectious diseases and public health.Frontiers in bioengineering and biotechnology · 2023Review
- Don't go breaking my…lungs? The acute respiratory distress syndrome is common, deadly, and probably underrecognized after cardiac arrest.Resuscitation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In the last 20 years, survival among patients with acute respiratory distress syndrome (ARDS) has increased substantially with advances in lung-protective ventilation and resuscitation. Building on this success, personalizing mechanical ventilation to patient-specific physiology for enhanced lung protection will be a top research priority for the years ahead. However, the ARDS research agenda must be broader in scope. Further understanding of the heterogeneous biology, from molecular to mechanical, underlying early ARDS pathogenesis is essential to inform therapeutic discovery and tailor treatment and prevention strategies to the individual patient. The ARDSne(x)t research agenda for the next 20 years calls for bringing personalized medicine to ARDS, asking simultaneously both whether a treatment affords clinically meaningful benefit and for whom. This expanded scope necessitates standard acquisition of highly granular biological, physiological, and clinical data across studies to identify biologically distinct subgroups that may respond differently to a given intervention. Clinical trials will need to consider enrichment strategies and incorporate long-term functional outcomes. Tremendous investment in research infrastructure and global collaboration will be vital to fulfilling this agenda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.